Home > News > Headline News > Archive

Click on title to read the full article.

NCI Cancer Bulletin

June 26, 2012

By June 26, 2012 • Volume 9 / Number 13

The National Cancer Institute's Latest Cancer Bulletin for June 26, 2012.

New Jersey Clinical Trial Focuses on New Drug for Metastatic Breast Cancer

June 19, 2012

By Newswise

Researchers at The Cancer Institute of New Jersey (CINJ) are enrolling patients for a clinical trial, which aims to evaluate a new drug for breast cancer that has spread (metastatic) in combination with two chemotherapy agents called doxorubicin and cyclophosphamide. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.


Researchers Identify Need to Sample Multiple Tumor Zones in Breast Cancer

June 15, 2012

By Journal of Molecular Diagnostics

Certain short strands of RNA, known as microRNAs (miRNAs), have been linked to the progression and metastasis of breast cancer and may provide information about prognosis. However, studies of miRNA expression profiles often report conflicting findings. While the potential for using miRNAs in breast cancer diagnosis is promising, scientists report in a new study published online today in The Journal of Molecular Diagnostics that differences in the amount and types of miRNA within breast tumors can be misleading.


A Conversation with Dr. Patricia Steeg on Redesigning Clinical Trials to Test Therapies that Could Prevent Cancer Metastasis

June 12, 2012

A Conversation with Dr. Patricia Steeg on Redesigning Clinical Trials to Test Therapies that Could Prevent Cancer Metastasis

In a perspective published May 30 in Nature, Dr. Patricia Steeg argues that the current system for clinical trials must be redesigned if there is to be a decline in breast cancer metastasis, which is the leading cause of death from the disease. Dr. Steeg, who heads the Women's Cancers Section in NCI's Laboratory of Molecular Pharmacology, recently spoke with the NCI Cancer Bulletin about the challenges in developing treatments that prevent metastasis and her proposal for a new clinical trial design to test such therapies.


Breast cancer recurs in almost one in four patients, British study says

June 12, 2012

By Denis Campbell, The Guardian

Almost one in four women who develop breast cancer will see the disease return within 10 years, according to the first British study of how many sufferers confront the UK's commonest cancer twice. Research into 1,000 women who were first diagnosed with the disease between January 1999 and March 2002 and then had their health monitored for 10 years found it recurred in 22.6% of them.


A hint at novel breast cancer treatment from HIV drug

June 11, 2012

By Don Sapatkin, Inquirer Staff Writer

A potential pathway to breast cancer treatment discovered by researchers at Thomas Jefferson University contains so many intriguing elements that it is easy to lose count. Here are three:

It treats the cancer with existing HIV drugs. It operates not by killing cells or slowing their growth, but by blocking their journey to other parts of the body, where they become deadly. It works against a particularly aggressive category of breast cancers, known as triple negative, for which there are no targeted therapies.

FDA approves Perjeta for type of late-stage breast cancer

June 9, 2012

By FDA News Release

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

Intended for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy, Perjeta is combined with trastuzumab, another anti-HER2 therapy, and docetaxel, a type of chemotherapy.


Breast Cancer: Blood Test Spots Wayward Tumor Cells

June 6, 2012

By Kate Moisse, ABC World News

A simple blood test can help predict the recurrence of breast cancer, a new study has found. The question is: Will it save lives?

The test detects cancer cells in the blood that have broken free from a tumor in the breast, like seeds that have fallen from a tree.

Killing cancer without punishing the patient?

June 2, 2012

By Andrew Pollack, New York Times

Fern Saitowitz’s advanced breast cancer was controlled for about a year by the drug Herceptin and a toxic chemotherapy agent. But her hair fell out, her fingernails turned black and she was constantly fatigued.

She switched to an experimental treatment, which also consisted of Herceptin and a chemotherapy agent. Only this time, the two drugs were attached to each other, keeping the toxic agent inactive until the Herceptin carried it to the tumor. Side effects, other than temporary nausea and some muscle cramps, vanished.